Li Laboratory for Cancer Diagnostic Innovation Research

The Li Laboratory for Cancer Diagnostic Innovation Research specializes in the multi-omics analysis of pediatric tumors using state-of-the-art technologies, such as next-generation sequencing, and other genomic tools. The driving force behind their research is the identification of mutations and signature genomic alterations that can aid in cancer diagnosis, monitor disease progression, and optimize treatment strategies for children with cancer. The lab performs translational research to quickly translate new technologies and knowledge into patient care to support clinical trials and the development of new therapies. The long-term goal of this research is to expand the database and knowledge of the multi-omics signature of different pediatric cancers, with the ultimate goal of being able to design personalized cures for every patient with cancer.

A greater understanding of the mechanics of cancer genome/transcriptome/ methylome/circulome/proteome will not only guide patient treatment but also aid in the development of new molecular diagnostic tests to screen children who may be at risk of developing cancer so that the disease can be detected before it has a chance to take hold.

The Li Lab has developed cell-free DNA technology-based assays, also known as liquid biopsy, to reduce the need for invasive tissue biopsies as well as provide a solution for those tumors where such biopsies are not possible. This method of non-invasive sampling also carries a good deal of potential for cancer screening.

Learn more about our research